Wang Tian-Shu, Jing Li-Jun
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
World J Psychiatry. 2024 May 19;14(5):644-652. doi: 10.5498/wjp.v14.i5.644.
Cerebral infarction (CI) is characterized by a high prevalence, disability, and mortality. Timely or improper treatment greatly affects patient prognosis.
To explore the drug efficacy of aspirin plus edaravone and to explore their effect on quality of life (QOL), anxiety and depression in CI patients.
We retrospectively analyzed the records of 124 CI patients treated between June 2019 and February 2021 who were assigned to an observation group (OG) (combination therapy of aspirin and edaravone, 65 patients) or a control group (CG) (aspirin monotherapy, 59 patients). The therapeutic effects, pre- and posttreatment National Institutes of Health Stroke Scale (NIHSS) scores, activities of daily living, degree of cognitive impairment, protein levels of glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE) and S-100B, occurrence of adverse reactions, and serum high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α were evaluated, detected and compared between the two groups. Finally, posttreatment QOL, anxiety, and depression were assessed by the Medical Outcomes Study 36- Item Short Form Health Survey Scale, Self-rating Depression Scale (SDS), and Self-rating Anxiety Scale (SAS), respectively.
Compared with the CG, the OG had markedly better therapeutic effects, greater improvements in activities of daily living, and better alleviation in cognitive dysfunction after treatment, as well as lower posttreatment NIHSS scores and serum NSE, GFAP, S-100B, hs-CRP, IL-6, and TNF-α levels; the OG was similar to the CG in terms of adverse reactions but was better than the CG in terms of posttreatment QOL; and the OG also had lower SDS and SAS scores than the CG after treatment.
Aspirin plus edaravone had a good curative effect on CI. It can reverse cranial nerve damage in patients, improve neurological function and prognosis, and alleviate inflammation, anxiety, and depression; thus, it is considered safe and worthy of clinical application.
脑梗死（CI）具有高患病率、致残率和死亡率的特点。及时或不当的治疗会极大地影响患者预后。
探讨阿司匹林联合依达拉奉的药物疗效，并探讨其对CI患者生活质量（QOL）、焦虑和抑郁的影响。
我们回顾性分析了2019年6月至2021年2月期间接受治疗的124例CI患者的记录，这些患者被分为观察组（OG）（阿司匹林和依达拉奉联合治疗，65例患者）或对照组（CG）（阿司匹林单药治疗，59例患者）。评估、检测并比较两组患者的治疗效果、治疗前后的美国国立卫生研究院卒中量表（NIHSS）评分、日常生活活动能力、认知障碍程度、胶质纤维酸性蛋白（GFAP）、神经元特异性烯醇化酶（NSE）和S-100B的蛋白水平、不良反应的发生情况以及血清高敏C反应蛋白（hs-CRP）、白细胞介素（IL）-6和肿瘤坏死因子（TNF）-α。最后，分别采用医学结局研究36项简短健康调查量表、自评抑郁量表（SDS）和自评焦虑量表（SAS）评估治疗后的QOL、焦虑和抑郁情况。
与CG相比，OG治疗效果明显更好，治疗后日常生活活动能力改善更大，认知功能障碍缓解更好，治疗后NIHSS评分以及血清NSE、GFAP、S-100B、hs-CRP、IL-6和TNF-α水平更低；OG在不良反应方面与CG相似，但在治疗后QOL方面优于CG；治疗后OG的SDS和SAS评分也低于CG。
阿司匹林联合依达拉奉对CI有良好的治疗效果。它可以逆转患者的脑神经损伤，改善神经功能和预后，减轻炎症、焦虑和抑郁；因此，被认为是安全的，值得临床应用。
